Project Grant F31CA290897
Award Date 12/1/25
Completion Date 4/16/27
Dollars Obligated $140K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
- This federal Project Grant award of $185,760 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) aims to support research to investigate the role of glycerol metabolism in anti-tumor immunity. The research, conducted by the University of Chicago, will determine the immunomodulatory effects of glycerol on CD8+ T cells and examine the metabolic interactions between cancer cells and T cells. The project will also explore methods to improve anti-tumor immunity by...
- This Project Grant award, funded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), aims to investigate the potential of a de novo dietary compound called Sumiki's Acid (SKA) as an immunomodulator for cancer immunoprevention. The $113,203 award, granted on August 1, 2025, will support research to determine SKA's ability to enhance natural killer (NK) cell activation and cytotoxicity against cancer cells, as well as evaluate its cancer-preventive effects in mouse models. The...
- The Project Grant award of $424,734 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of a novel spatial proteomics approach to profile immune cell types and their locations within a tumor microenvironment. The University of Illinois, the awardee, aims to integrate 3D microscopy techniques with bottom-up proteomic assays to offer deep proteome profiles of specific immune cells at various subregions of a mouse tumor (Aims 1 and 2). The goal is...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The University of Chicago received a $372,628 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on September 12, 2025. The grant funds the development of a large-format spatial transcriptomics profiling platform, called Array-Seq, to enable detailed spatiomolecular analysis of human cancer samples. This technology aims to overcome limitations of existing spatial transcriptomics methods by increasing throughput, sample size compatibility, and...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the immunological mechanisms and functional potential of memory-phenotype CD8+ T cells in the context of infection and cancer. The $108,512 award, made on August 25, 2025, will enable researchers at the University of Chicago to investigate how these CD8+ T cells differentiate and acquire unique...
- This $147,486 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research at the University of Pittsburgh to understand the impact of altered lipid metabolism on CD8 T cell exhaustion within the tumor microenvironment. The project aims to investigate how increased lipid accumulation influences the differentiation and function of CD8 T cells, which play a key role in anti-tumor immune responses. This 3-year project, running from...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
This $139,917 federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research to investigate how the dietary nutrient zeaxanthin enhances anti-tumor immunity by reprogramming CD8+ T cell function. The award recipient, the University of Chicago, will conduct preclinical studies to demonstrate zeaxanthin's anti-tumor effects and elucidate the underlying molecular mechanisms through which it impacts CD8+ T cell activity. The research aims to advance the understanding of how dietary factors can influence the effectiveness of cancer immunotherapy. The award period runs from December 1, 2025 to April 16, 2027.
Generated 10/21/25, 5:08 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $564 | 5/28/25 | ||
| Not listed | $564 | 5/28/25 | ||
| Not listed | $0 | 5/28/25 | ||
| Not listed | $46.3k | 4/17/25 | ||
| Not listed | $46.3k | 4/17/25 |